Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa
| dc.rights.license | open | en_US |
| dc.contributor.author | BOYD, A. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOH, Desmorys Raoul | |
| dc.contributor.author | MAYLIN, S. | |
| dc.contributor.author | ABDOU CHEKARAOU, M. | |
| dc.contributor.author | MAHJOUB, N. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GABILLARD, Delphine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ANGLARET, Xavier | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | EHOLIE, Serge Paul | |
| dc.contributor.author | DELAUGERRE, C. | |
| dc.contributor.author | DANEL, C. | |
| dc.contributor.author | ZOULIM, F. | |
| dc.contributor.author | LACOMBE, K. | |
| dc.date.accessioned | 2020-10-26T15:04:59Z | |
| dc.date.available | 2020-10-26T15:04:59Z | |
| dc.date.issued | 2018-10 | |
| dc.identifier.issn | 1365-2893 (Electronic) 1352-0504 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/11480 | |
| dc.description.abstractEn | The nucleotide substitution G1896A on the precore (pc) region has been implicated in virological and serological responses during treatment in hepatitis B virus (HBV)-infected patients. Whether this mutation affects the therapeutic course of HIV-HBV co-infected patients, especially from Western Africa, is unknown. In this prospective cohort study, 86 antiretroviral (ARV)-naive HIV-HBV co-infected patients from Cote d'Ivoire, initiating ARV-treatment containing lamivudine (n=53) or tenofovir (n=33), had available baseline pc sequences. Association of the pcG1896A mutation with time-to-undetectable HBV-DNA, hepatitis B "e" antigen (HBeAg)-seroclearance (in HBeAg-positive patients), and hepatitis B surface antigen (HBsAg)-seroclearance was evaluated using Cox proportional hazards regression. At ARV-initiation, median HBV-DNA was 6.04 log10 copies/mL (IQR=3.70-7.93) with 97.7% harboring HBV genotype E. Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg-negative (p<0.001) and had basal core promotor A1762T/ G1764A mutations (p<0.001). Patients were followed for a median 36 months (IQR=24-36). Cumulative proportion of undetectable HBV-DNA was significantly higher in patients with baseline mutation (pcG1896A=86.6% versus no pcG1896A=66.9%, p=0.04), but not after adjusting for baseline HBV-DNA levels and anti-HBV agent (p=0.2). No difference in cumulative proportion of HBeAg-seroclearance was observed between mutation groups (pcG1896A=57.1% versus no pcG1896A=54.3%, p=0.7). Significantly higher cumulative proportion of HBsAg-seroclearance was observed in patients without this mutation (pcG1896A=0% versus no pcG1896A=36.9%, p<0.001), even after adjusting for baseline HBsAg-quantification and anti-HBV agent (p<0.001). In conclusion, lacking the pcG1896A mutation before ARV-initiation appeared to increase HBsAg-seroclearance rates during treatment. The therapeutic implications of this mutation need further exploration in this setting. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | IDLIC | |
| dc.title.en | Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa | |
| dc.title.alternative | J Viral Hepat | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/jvh.12914 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29660214 | en_US |
| bordeaux.journal | Journal of viral hepatitis | en_US |
| bordeaux.page | 1121-1131 | en_US |
| bordeaux.volume | 25 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 10 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.date=2018-10&rft.volume=25&rft.issue=10&rft.spage=1121-1131&rft.epage=1121-1131&rft.eissn=1365-2893%20(Electronic)%201352-0504%20(Linking)&rft.issn=1365-2893%20(Electronic)%201352-0504%20(Linking)&rft.au=BOYD,%20A.&MOH,%20Desmorys%20Raoul&MAYLIN,%20S.&ABDOU%20CHEKARAOU,%20M.&MAHJOUB,%20N.&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||